The global heart failure medical devices market was estimated at ~$6 billion in 2024 and several factors will drive its growth over the next few years. The patient population with heart disease is expected to grow relative to other adjacent patient populations due to the aging US and EU populations, and the increasing obese and overweight population in both regions.

In this article, we focus specifically on the segment of the cardiology medical devices market concerning heart failure therapeutics. Our expert, Akash Karopadi, breaks down the forces shaping the heart failure medical devices landscape, the emerging technologies driving innovation, and the key challenges on the road ahead.

Growth Projections and Drivers

The heart failure medical devices market is experiencing continued growth driven by technological advancements and some strategic acquisitions. Major drivers include population age and disease burden, as well as new pharmaceuticals.  

Valued over $20 billion in 2023, the global heart failure market is set to reach ~$40 billion by 2032, with a 6+% CAGR. Heart failure prevalence is currently continuing to rise due to an aging population as well as the burden of chronic conditions. The new era of diabetes and weight loss drugs could exert a long-term downward pressure on heart failure incidence.

Emerging Innovations and Impact on Care

Innovative technologies, including advances in medical devices, pharmaceuticals, and digital solutions, will continue to transform heart failure treatment and management. Here are the innovations that will have the greatest impact on care in the next few years.

• Advancements in mechanical circulatory support for heart failure include device miniaturization, enhanced biocompatibility, integration of smart technologies, and personalized adaptive systems.
• Diabetes and weight loss drugs are showing promise in Heart Failure with Preserved Ejection Fraction management, with Sodium-Glucose Cotransporter 2 inhibitors already guideline-recommended and Glucagon-Like Peptide-1 agonists demonstrating potential benefits, particularly in obese patients.
• Digital solutions will also help empower patients to better manage heart failure using non-invasive tools while enabling real-time data sharing with healthcare providers for timely interventions.

Key Challenges in the Heart Failure Medical Devices Market

Key challenges hindering this market revolve around the high costs associated with advanced devices, reimbursement challenges, and access to care. Providers face obstacles like specialist shortages and financial strain from readmission penalties.

• The Heart Failure Society of America highlights the escalating economic burden projected to reach $70 billion per year by 2030, with emergency department visits and hospital admissions as significant cost contributors.
• The Centers for Medicare and Medicaid Services (CMS) is expected to continue reimbursement cuts through 2025, straining hospital finances already impacted by readmission penalties via the Hospital Readmissions Reduction Program.
• In response to the ongoing cardiologist shortage, CMS recently expanded the range of practitioners authorized to supervise cardiac rehabilitation, aiming to improve access and mitigate workforce strain.

Heart Failure Medical Devices Market Outlook

Despite challenges, the heart failure medical devices market continues to see sustained innovation, with emerging trends shifting away from one-size-fits-all models toward patient-centered approaches advocated by regulatory bodies like the Food and Drug Administration. This includes instances of tailoring devices to the unique physiological needs of women and children, addressing factors such as size, hormonal variations, and distinct heart failure progression patterns.

How Alira Health Can Help

Navigating the dynamic cardiology space requires strategies that address regulatory pathways, reimbursement challenges, clinical development, and market execution. Alira Health partners with clients to overcome these complexities, leveraging our multidisciplinary team of clinician-scientists and GTM experts. From defining optimal market access strategies and streamlining reimbursement to translating innovative therapies from bench to bedside, we deliver tailored solutions that ensure real-world adoption and long-term success. Contact us to learn more.

Resources

• Congestive Heart Failure Treatment Devices Market Size, Share & Trends Analysis Report By Product (Ventricular Assist Devices, Implantable Cardioverter Defibrillators, Counter Pulsation Devices, Pacemakers), By Region, And Segment Forecasts, 2025 – 2030
• Congestive Heart Failure (CHF) Treatment Devices Market – By Product (Defibrillator [ICD, External], Pacemaker, Cardiac Resynchronization Therapy Device, Ventricular Assist Device [LVAD, RVAD]), End-use (Hospital, Cardiac Clinic) – Global Forecast 2024 – 2032
• Edwards spends $1.2B on 2 heart device firms, extending deal streak
• Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
• J&J to buy heart failure implant maker V-Wave for up to $1.7B
• Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
• FDA Approves Medtronic’s Extravascular Defibrillator for Ventricular Arrhythmia
• Mounjaro and Zepbound Cut Risks of Heart Failure, Early Data Shows
• Abbott CardioMEMS HF System – Remote Pulmonary Pressure Monitor
• Congestive Heart Failure Treatment Device Market by Product, End-User – Global Forecast 2025-2030
• CMS increases reimbursement for AI-powered heart failure platform
• CMS Change Request 13513: Pulmonary Rehabilitation, Cardiac Rehabilitation and Intensive Cardiac Rehabilitation (PR/CR/ICR) Expansion of Supervising Practitioners
• Cardiologists speak out about reimbursement cuts, say Congress ‘left clinicians holding the bag’
• Heart of Health Policy | Cuts Continue: CMS Releases Proposed 2025 Medicare Physician Fee Schedule
• Proposed 2025 Medicare Physician Fee Schedule Deep Dive